Back

Predictors of hospitalization and early emergency department revisit in patients with pericardial syndromes: the PES-ED Study

28 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Advancing understanding in pericardial disease Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Lorenzo Pelagatti

Careggi University Hospital (AOUC), Florence (Italy)

6 More presentations in this session

Presentation thumbnail
Independent prognostic value of pericardial fluid lactate dehydrogenase beyond malignancy in patients undergoing pericardiocentesis: a multicenter registry study
Doctor J. Ahn (Changwon, KR)
Presentation thumbnail
Nationwide outcomes after first-time pericarditis: recurrence, rehospitalization, and mortality in a danish registry cohort
Doctor R. Stokholm Baekgaard (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Diagnostic and prognostic significance of pericardial fluid biomarkers and a novel tumor-inflammation index in patients undergoing pericardiocentesis
Doctor C. Korucu (Sanliurfa, TR)
Abstract Slides
Presentation thumbnail
Real-world performance of postpericardiotomy syndrome diagnostic criteria – an analysis of the prospective CAREBANK database
Miss N. Vasarainen (FI)
Abstract Slides Video
Presentation thumbnail
Association of etiology of pericardial fluid with mortality
Mr A. Kane (Rochester, US)
Abstract Slides Video

Access the full session

Session thumbnail
Advancing understanding in pericardial disease

The Event

Event poster

ESC Congress 2026

28 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Acute pericarditis: who should stay and who should go?
28 August 2020
thumbnail
Congress Presentation
History of prior cardiac surgery confers lower risk of pericardial effusion following leadless pacemaker implantation: Insights from a large, real-world dataset
13 April 2026
thumbnail
Congress Presentation
Does early initiation of non-statin therapy, evolocumab with LDL-C <50mg/dL contribute to the reduction of hospital readmissions in patients with ACS?: a single center real world evidence from ELAINE
4 April 2025
thumbnail
Congress Presentation
Predictors for 30-day rehospitalisation in advanced heart failure: a single-centre prospective cohort study
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources